Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASKET PSMA: PSMA PET/CT in Solid Tumors
NCT03453528Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2017
- Primary completion
- Dec 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of gallium ga-68 gozetotide in metastatic castration-resistant prostate cancer (mCRPC) and solid tumor, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Detection Rate of 68Ga-PSMA PET/CT up to 36 months. Started Jul 2017; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)solid tumor
Beyond the preview
Go deeper on NCT03453528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453528.